Spinal cord stimulation: panacea for incurable diseases?

Abstract

A spinal cord stimulator is usually used as an electro-modulator for pain treatment. Shealy et al. [1] first reported the use of a spinal cord stimulator in an elderly male suffering with terminal bronchogenic carcinoma and right-sided chest pain in 1967. Since then, spinal cord stimulation (SCS) has been applied to many disease entities, such as neuropathic pain, failed back surgery syndrome, complex regional pain syndrome, and ischemic peripheral vascular disease [2-4]. The indications for SCS have been extended to include intractable angina pain, interstitial cystitis, intractable pain, headache, and non-painrelated applications such as refractory congestive heart failure, intractable spasticity, or treatment of cerebral vasospasm after subarachnoid hemorrhage [5-9]. SCS systems are composed of three components: leads/electrodes, a generator/power source, and a programmer/controller [5]. Leads can be divided into percutaneous leads and paddle leads. Small-sized rechargeable implanted batteries are becoming increasingly common. An electrical current is applied to the dorsal columns, creating a tingling sensation in the dermatomes whose afferent fibers traverse the regions being stimulated. The physician can control the degree, range of current, pulse width, and rate of the stimulation wave to optimize pain control. In this issue of the Korean Journal of Anesthesiology, Ryu et al. [10] report the effect of cervical SCS for treatment of digit ulcers in a patient with Buerger’s disease. Thromboangiitis obliterans is a type of segmental inflammatory vasculitis asso ciated with severe pain and ulcers, which involves the small or medium-sized arteries and veins. Treatment of this painful ulcer is difficult and often involves amputation of the affected limb. This case report suggests that cervical SCS is a good choice for reducing pain and healing of an ulcer in patients with vasculitis. There are some reports of the effectiveness of SCS for patients with Raynaud’s disease and Buerger’s disease [11-13]. Cook et al. [14] reported using electronic stimulation of spinal nerves and the dorsal root in patients with a vascular disease of the limbs. Since then, SCS has been successfully used to treat atherosclerotic and vasospastic peripheral arterial disease. SCS improves microcirculation by inhibiting sympathetic vasoconstriction. SCS reduces pain in Buerger’s disease by stimulating the secretion of a number of inhibitory neurotransmitters and promoting the secretion of gamma aminobutyric acid, substance P, and serotonin at the spinal nerve dorsal horn [15,16]. Wolter and Kieselbach [17] reported the long-term outcomes of patients with cervical SCS. Treatment indications included patients with causalgia, cervicobrachialgia, complex regional pain syndrome, phantom pain, and Raynaud’s syndrome [18]. Pain reduction and paresthesia coverage were effective in almost all patients, and treatment satisfaction was high. No severe complications, such as neurological deficits or infection, were reported. They concluded that cervical SCS appears to be a safe and efficacious treatment option for upper limb neuropathic pain. Nevertheless, SCS has some disadvantages. The procedure for implanting SCS is invasive, so it is associated with complications such as infection, bleeding, and dural puncture [19]. The effectiveness of SCS is limited, and regular checks and continuous follow-ups are needed. Furthermore, SCS is expensive because of the limited medical insurance coverage in Korea. However, SCS is cost effective as compared with conservative management alone in cases with medical insurance coverage. Advances in SCS technology and understanding of the